522 results on '"Hogan, William J."'
Search Results
2. Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
3. Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study
4. A validated risk stratification that incorporates MAGIC biomarkers predicts long term outcomes in pediatric patients with acute GVHD
5. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis
6. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
7. Severe Late Agranulocytosis Post-Allogeneic Stem Cell Transplant during Tacrolimus Taper
8. Factors Predicting Survival in Patients with TP53-Mutated Myeloid Neoplasms Following Allogeneic Stem Cell Transplant
9. Ibrutinib for Therapy of Steroid-Refractory Chronic Graft Vs. Host Disease: A Multicenter Real-World Analysis
10. Coronary Artery Calcium As a Predictor of Non-Relapse Mortality and Overall Survival in Patients Undergoing Post-Transplant Cyclophosphamide As Gvhd Prophylaxis
11. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms
12. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial
13. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
14. Chronic Graft-Versus-Host Disease Leptomeningitis Following Allogeneic Stem Cell Transplant.
15. Impact of Wilms Tumor (WT1) Mutation on Relapse and Overall Survival in Acute Myeloid Leukemia Patients Following Allogenic Stem Cell Transplantation
16. Outcomes of HLA-DPB1 Mismatch in Patients Receiving Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis
17. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome
18. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd
19. A Day 14 Endpoint for Acute GVHD Clinical Trials
20. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms
21. EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
22. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases
23. Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients
24. The utility of biomarkers in acute GVHD prognostication
25. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
26. Long-Term Pulmonary Function Trajectories After Allogeneic Bone Marrow Transplantation
27. Pulmonary function and long-term survival in patients with PERDS after autologous hematopoietic stem cell transplantation
28. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
29. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
30. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
31. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
32. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation
33. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
34. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
35. Risk Factors and Outcomes of Nocardiosis in Hematopoietic Stem Cell Transplantation Recipients
36. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience
37. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
38. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
39. Effective treatment of low-risk acute GVHD with itacitinib monotherapy
40. Prediction of Atrial Arrhythmia after Allogenic Transplantation Using Artificial Intelligence-Enabled ECG
41. Cpss Cytogenetics and Easix Score Based Composite Survival Model for Patients with CMML Undergoing Allogeneic Transplant
42. Efficacy of Donor Lymphocyte Infusions in Achieving Disease Control Among Myeloid Malignancy Patients Treated with an Allogeneic Hematopoietic Stem Cell Transplantation
43. Hematopoietic Stem Cell Transplant Outcome in STAG2-Mutated Myeloid Neoplasms
44. De Novo Late Acute Gvhd: Incidence, Outcomes, and Impact of Biomarkers Compared to Classic Acute Gvhd
45. Surrogates of Endothelial Injury Predict Non-Relapse Mortality Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
46. Differentiation of acute graft-versus-host disease from drug reaction in skin by a novel tissue-based biomarker assay
47. Oncologic Emergencies
48. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
49. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
50. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.